Jump Financial LLC Sells 727 Shares of Illumina, Inc. (NASDAQ:ILMN)

Jump Financial LLC reduced its holdings in Illumina, Inc. (NASDAQ:ILMNFree Report) by 19.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,961 shares of the life sciences company’s stock after selling 727 shares during the period. Jump Financial LLC’s holdings in Illumina were worth $406,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. State of Wyoming purchased a new stake in Illumina in the second quarter valued at $32,000. Quent Capital LLC grew its holdings in Illumina by 71.2% during the third quarter. Quent Capital LLC now owns 250 shares of the life sciences company’s stock worth $34,000 after acquiring an additional 104 shares during the period. ST Germain D J Co. Inc. purchased a new position in Illumina during the second quarter valued at approximately $36,000. Riverview Trust Co raised its position in Illumina by 203.5% during the third quarter. Riverview Trust Co now owns 261 shares of the life sciences company’s stock valued at $36,000 after acquiring an additional 175 shares in the last quarter. Finally, WFA of San Diego LLC acquired a new position in Illumina in the second quarter valued at approximately $37,000. Institutional investors and hedge funds own 92.17% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of a number of recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $258.00 price objective on shares of Illumina in a report on Friday. Guggenheim assumed coverage on Illumina in a research note on Thursday, December 14th. They issued a “buy” rating and a $155.00 price target for the company. Barclays increased their price target on Illumina from $50.00 to $80.00 and gave the stock an “underweight” rating in a research report on Thursday, January 25th. Wolfe Research started coverage on Illumina in a research report on Wednesday, December 13th. They set an “outperform” rating and a $175.00 target price on the stock. Finally, Stephens assumed coverage on shares of Illumina in a research report on Thursday, December 14th. They set an “overweight” rating and a $170.00 price objective for the company. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $166.95.

Check Out Our Latest Analysis on ILMN

Illumina Stock Performance

Shares of ILMN stock opened at $137.84 on Monday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.28 and a current ratio of 1.69. The firm has a market cap of $21.89 billion, a P/E ratio of -18.78, a P/E/G ratio of 24.83 and a beta of 1.22. The firm’s 50 day moving average price is $135.24 and its 200-day moving average price is $137.59. Illumina, Inc. has a one year low of $89.00 and a one year high of $238.55.

Illumina (NASDAQ:ILMNGet Free Report) last issued its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. Illumina had a positive return on equity of 2.15% and a negative net margin of 25.78%. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the previous year, the firm posted $0.14 earnings per share. The company’s revenue was up 3.6% on a year-over-year basis. As a group, equities research analysts predict that Illumina, Inc. will post 1.03 EPS for the current year.

About Illumina

(Free Report)

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

See Also

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.